+

US20010031785A1 - Use of zinc tranexamate in the treatment of diabetes - Google Patents

Use of zinc tranexamate in the treatment of diabetes Download PDF

Info

Publication number
US20010031785A1
US20010031785A1 US09/799,692 US79969201A US2001031785A1 US 20010031785 A1 US20010031785 A1 US 20010031785A1 US 79969201 A US79969201 A US 79969201A US 2001031785 A1 US2001031785 A1 US 2001031785A1
Authority
US
United States
Prior art keywords
diabetes
zinc
glucose
blood sugar
zinc tranexamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/799,692
Other versions
US6358999B2 (en
Inventor
Hajime Fujimura
Masakatsu Nozaki
Shun-ichi Tanaka
Reiko Natsuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamari Chemicals Ltd
Original Assignee
Hamari Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamari Chemicals Ltd filed Critical Hamari Chemicals Ltd
Assigned to HAMARI CHEMICALS, LTD., OF reassignment HAMARI CHEMICALS, LTD., OF ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NATSUKI, REIKO, NOZAKI, MASAKATSU, TANAKA, SHAN-ICHI, FUJIMURA, HAJIME
Publication of US20010031785A1 publication Critical patent/US20010031785A1/en
Application granted granted Critical
Publication of US6358999B2 publication Critical patent/US6358999B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • This invention relates to use of a zinc tranexamate compound in the treatment of diabetes. More particularly, it relates to use of a zinc tranexamate compound in the treatment of diabetes as an ⁇ -glucosidase inhibitor and also as a drug for treating insulin-resistant type II diabetes.
  • ⁇ -glucosidase inhibitors are of current interest in the treatment of diabetes ⁇ -Glucosidase is an enzyme which acts on poly- and oligosaccharides to hydrolyze into their constituent monosaccharides. Administration of an ⁇ -glucosidase inhibitor may delay the absorption of glucose through digestive tract by inhibiting the enzyme in vivo.
  • Known oral hypoglycemic drugs including SU may result in acute hypoglycemic conditions when an excessive dose is administered and exhibit a variety of their own adverse effects.
  • Known ⁇ -glucosidase inhibitors may produce high incidence of gastrointestinal side effects and present, therefore, a number of problems upon long term administration. All of the above drugs are not effective in the treatment of insulin-resistant type II diabetes.
  • Antidiabetics in general are administered for a long term and thus require low incidence of adverse effects.
  • the present invention provides a method for the treatment of diabetes comprising orally administering a therapeutically effective amount of a zinc tranexamate compound to a patient with diabetes.
  • the present invention is directed to use of a zinc tranexamate compound in the manufacture of a medicament for treating diabetes in human subjects.
  • Tranexamic acid chemically trans-1-(aminomethyl)cyclohexanecarboxylic acid
  • Two moles of this acid form a stable salt with one atom of zinc, called “zinc tranexamate”.
  • the zinc salt in turn, forms a water-soluble complex with a physiologically nontoxic organic acid such as acetic, glycolic, lactic, succinic, malic, tartaric, maleic or fumaric acid.
  • a physiologically nontoxic organic acid such as acetic, glycolic, lactic, succinic, malic, tartaric, maleic or fumaric acid.
  • the term “zinc tranexamate compounds” includes zinc tranexamate either anhydrous or hydrated form and its complex with an organic acid.
  • Zinc tranexamate compounds were first synthesized and found to have antiinflammatory and antiulcerative activities by Fujimura et al. See, JP-B-0702524 and U.S. Pat. No. 5,506,264. It was not known, however, that either tranexamic acid or zinc tranexamate compounds are effective in the treatment of diabetes.
  • mice Each group consisting of five mice was fasted for 17-24 hours and then Y-4 was orally administered at varying doses. After 30 minutes, mice were given glucose orally at a dose of 1 g/kg body weight. Blood samples were collected from the tail end of mice at different time intervals and assayed for blood sugar levels using GLUTESTTM sensor available from Matsushita Kotobuki Electronic Industry Company. Y-4 suppressed elevation of blood sugar level as shown in Table 1 below. TABLE 1 Suppressive effect of Y-4 on the elevation of blood sugar level after glucose loading Dose (mg/ Blood sugar level (mg/dl) kg) 20 min. 40 min. 60 min. 120 min. 180 min.
  • mice Each group consisting of five mice was fasted for 17-24 hours and then Y-4 was orally administered at varying doses.
  • mice were orally given 1 g/kg body weight of sucrose 30 minutes after the administration of Y-4 or 2 g/kg body weight of sucrose 2 hours after the administration of Y-4.
  • blood samples were collected from the tail end of mice at different time intervals and assayed for blood sugar levels.
  • Table 2 shows the results of administration of the test compound 30 minutes before sucrose loading
  • Table 3 shows the results of administration of the test compound 2 hours before sucrose loading, respectively.
  • a significant suppressive effect on the elevation of blood sugar level was observed in a dose responsive manner and delayed absorption of sucrose was demonstrated in groups given 100 mg/kg and 200 mg/kg of Y-4 30 minutes before sucrose loading up to 90 minutes after the sucrose loading as shown in Table 2.
  • mice were orally given Y-4 at varying doses 30 minutes before loading 2 g/kg of sucrose. After sucrose loading, blood samples were collected and assayed for blood sugar levels at different time intervals as in the preceding examples. The results are shown in Table 4. Administration of Y-4 30 minutes before sucrose loading remarkably suppressed the elevation of blood sugar level up to 3 hours. TABLE 4 Suppressive effect of Y-4 on the elevation of sugar level in mice having experimental diabetes after sucrose loading Dose Blood sugar level (mg/dl) (mg/kg) 20 min. 40 min.
  • STZ streptozocin
  • Y-4 was orally administered to the mice having experimental diabetes at a dose of 100 mg/kg 30 minutes before loading of 2 g of sucrose. Blood sugar and insulin levels in blood samples collected 30 minutes after sugar loading are shown in FIG. 1 and FIG. 2, respectively. Administration of Y-4 30 minutes before sucrose loading suppressed the elevation of blood sugar level almost completely whereas insulin level increased to a value which is not significantly different from the control value of normal mice group.
  • Intestinal tract enucleated from a normal mouse was homogenized by the conventional method after removing membrane mucosa.
  • a substrate sucrose, starch, maltose or isomaltose was used.
  • the homogenate was incubated with the substrate in the presence of a test compound (Y-4 or zinc chloride) at 37° C. for 30 minutes.
  • the reaction mixture was centrifuged and the glucose concentration in the resulting supernatant was assayed.
  • the glucose assay was conducted calorimetrically by adding a chromogenic reagent (0.47 mol/l of orthotoluidine, 16 mol/l of acetic acid, 10 mmol/l of boric acid) to the supernatant, heating the mixture in a boiling water bath for 8 minutes and measuring the absorbance at 635 nm.
  • ⁇ -Glucosidase activity expressed in terms of glucose concentration/mg protein was calculated. The results are shown in Table 5 through Table 8 below.
  • Y-4 inhibited ⁇ -glucosidase activity in the reaction with all substrates at a concentration higher than 5 mM in a dose responsive manner.
  • Zinc chloride used for comparative purpose was as effective as Y-4 to inhibit the enzymatic reaction with sucrose but not effective with other substrates.
  • TABLE 5 Inhibition of glucose production from sucrose (normal mouse) Inhibitor concentration Glucose (mg/mg protein) (mM) ZnCl 2 Y-4 0 5.239 ⁇ 0.073 5.239 ⁇ 0.073 5 3.509 ⁇ 0.254 4.078 ⁇ 0.073 10 1.658 ⁇ 0.078 1.682 ⁇ 0.097 30 0.714 ⁇ 0.097 0.726 ⁇ 0.157 50 0.133 ⁇ 0.024 0.436 ⁇ 0.036
  • Example 5 was repeated using intestinal tract enucleated from a diabetic mouse induced by the treatment with streptozocin instead of intestinal tract enucleated from a normal mouse to determine the inhibitory effect of Y-4 on ⁇ -glycosidase activity.
  • the results are shown in Table 9 through Table 12 below.
  • the intestinal ⁇ -glucosidase activity was higher in streptozocin-induced diabetic mouse than in normal mouse.
  • Y-4 remarkably inhibited the enzyme in the reaction with all substrates.
  • the inhibitory effect of Y-4 was more remarkable in the diabetic mouse than in normal mouse.
  • ZnCl 2 used for comparative purpose showed only weak inhibitory effects.
  • Y-4 was orally administered to male Wistar fatty rats (WFR) having tyep II diabetes with obesity and hyperlipidemia at an average daily dose of 150 mg/kg for consecutive 8 weeks. Eight weeks after the initiation of administration, the rats were fasted for 20 hours and then given oral administration of 2.5 g/kg/rat of glucose. Blood samples were collected from the tail vein at 30, 60, 120 and 180 minutes after the administration of glucose for assaying blood sugar and insulin levels. The results are shown in FIG. 3 and FIG. 4, respsectively. The blood sugar level was significantly controlled in the group treated with Y-4 as shown in FIG. 3 and the insulin level was normalized in the same group as shown in FIG. 4. This demonstrates that long term administration of Y-4 may improve the insulin resistance.
  • Y-4 zinc tranexamate monohydrate
  • Zinc tranexamate or monohydrate thereof may be orally administered either in the form of solid preparations such as tablets, granules, powders or capsules or in the form of liquid preparations such as syrups or other liquid preparations.
  • Zinc tranexamate is known to form a water-soluble complex with a physiologically nontoxic organic acid such as acetic, glycolic, lactic, succinic, malic, tartaric maleic or fumaric acid.
  • Liquid preparations may be formulated using this soluble complex.
  • These solid and liquid preparations may be produced using the method well-known in the art by processing the active ingredient with a pharmaceutically acceptable carrier.
  • the dose may vary depending on the conditions of the disease, age and body weight of a particular patient and generally lies between 300 mg and 2,000 mg as zinc tranexamate per day for adult patients. This daily dose may be divided into 3 to 4 fractions for oral administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A new use of a zinc tranexamate compound in the treatment of diabetes is disclosed. Oral administration of the compound adequately slows down absorption of glucose from digestive tracts by inhibiting α-glucosidase in vivo. The zinc tranexamate compound is also effective in the treatment of insulin-resistant type II diabetes.

Description

    FIELD OF THE INVENTION
  • This invention relates to use of a zinc tranexamate compound in the treatment of diabetes. More particularly, it relates to use of a zinc tranexamate compound in the treatment of diabetes as an α-glucosidase inhibitor and also as a drug for treating insulin-resistant type II diabetes. [0001]
    • BACKGROUND OF THE INVENTION
  • In the past, it had been recommended to treat patients with type II diabetes by the diet and/or exercise therapy to control their blood sugar levels before starting drug therapy. Because the insulin-secreatory function of the patient gradually decreases as the disease proceeds, it is current practice to positively control the blood sugar level of the patients from the early stage of diabetes. [0002]
  • Known therapeutic agents for diabetes include insulin preparations and oral hypoglycemic agents such as sulfonyl ureas (SU). In addition, α-glucosidase inhibitors are of current interest in the treatment of diabetes α-Glucosidase is an enzyme which acts on poly- and oligosaccharides to hydrolyze into their constituent monosaccharides. Administration of an α-glucosidase inhibitor may delay the absorption of glucose through digestive tract by inhibiting the enzyme in vivo. [0003]
  • Known oral hypoglycemic drugs including SU may result in acute hypoglycemic conditions when an excessive dose is administered and exhibit a variety of their own adverse effects. Known α-glucosidase inhibitors may produce high incidence of gastrointestinal side effects and present, therefore, a number of problems upon long term administration. All of the above drugs are not effective in the treatment of insulin-resistant type II diabetes. [0004]
  • Antidiabetics in general are administered for a long term and thus require low incidence of adverse effects. A need exists for a new α-glucosidase-inhibiting antidiabetic drug which is safe and retards elevation of blood sugar level of diabetic patients after taking a meal without affecting their normal blood sugar levels by adequately delaying the absorption of glucose from digestive tracts. It is also desirable to provide a drug which is effective to treat insulin-resistant type II diabetes. [0005]
    • SUMMARY OF THE INVENTION
  • In one aspect, the present invention provides a method for the treatment of diabetes comprising orally administering a therapeutically effective amount of a zinc tranexamate compound to a patient with diabetes. [0006]
  • In another aspect, the present invention is directed to use of a zinc tranexamate compound in the manufacture of a medicament for treating diabetes in human subjects. [0007]
    • DETAILED DESCRIPTION OF THE INVENTION
  • Tranexamic acid, chemically trans-1-(aminomethyl)cyclohexanecarboxylic acid, is an antiplasminic hemostatic agent. Two moles of this acid form a stable salt with one atom of zinc, called “zinc tranexamate”. The zinc salt, in turn, forms a water-soluble complex with a physiologically nontoxic organic acid such as acetic, glycolic, lactic, succinic, malic, tartaric, maleic or fumaric acid. As used herein, the term “zinc tranexamate compounds” includes zinc tranexamate either anhydrous or hydrated form and its complex with an organic acid. [0008]
  • Zinc tranexamate compounds were first synthesized and found to have antiinflammatory and antiulcerative activities by Fujimura et al. See, JP-B-0702524 and U.S. Pat. No. 5,506,264. It was not known, however, that either tranexamic acid or zinc tranexamate compounds are effective in the treatment of diabetes. [0009]
  • Suprisingly, we have discovered through a series of animal tests that zinc tranexamate compounds have a delaying effect on the absorption of glucose from digestive tracts by inhibiting α-glucosidase in vivo that leads to remarkable suppression of blood sugar levels in animals with experimental diabetes after loading the animals with a substrate sugar. We have also discovered that insulin resistance in rats with insulin-resistant type II diabetes was ameliorated by the oral administration of a zinc tranexamate compound. Details of the animal tests are given in the following examples in which zinc tranexamate monohydrate (Y-4) was used in the form of a suspension in 0.5% aqueous CMC solution unless otherwise indicated.[0010]
    • EXAMPLES
  • 1. Suppresive effect of Y-4 on the elevation of blood sugar level after glucose loading [0011]
  • Each group consisting of five mice was fasted for 17-24 hours and then Y-4 was orally administered at varying doses. After 30 minutes, mice were given glucose orally at a dose of 1 g/kg body weight. Blood samples were collected from the tail end of mice at different time intervals and assayed for blood sugar levels using GLUTEST™ sensor available from Matsushita Kotobuki Electronic Industry Company. Y-4 suppressed elevation of blood sugar level as shown in Table 1 below. [0012]
    TABLE 1
    Suppressive effect of Y-4 on the elevation of blood
    sugar level after glucose loading
    Dose
    (mg/ Blood sugar level (mg/dl)
    kg) 20 min. 40 min. 60 min. 120 min. 180 min.
    Con-  64.8 ± 4.2  78.4 ± 3.0 74.9 ± 2.5 56.0 ± 1.5 50.8 ± 2.1
    trol
     0 104.0 ± 1.1 127.6 ± 7.1 103.2 ± 3.3  73.6 ± 3.0 68.8 ± 6.1
     50  96.0 ± 3.5 104.8 ± 7.1  99.0 ± 14.0 78.4 ± 6.4 58.4 ± 6.0
    100  89.0 ± 2.9 112.6 ± 5.0 97.6 ± 0.9 73.1 ± 2.5 52.1 ± 1.9
    200  83.0 ± 4.1  95.2 ± 3.6 84.4 ± 2.8 66.2 ± 3.3 53.9 ± 2.1
  • 2. Suppressive effect of Y-4 on the elevation of blood sugar level after sucrose loading [0013]
  • Each group consisting of five mice was fasted for 17-24 hours and then Y-4 was orally administered at varying doses. [0014]
  • Mice were orally given 1 g/kg body weight of [0015] sucrose 30 minutes after the administration of Y-4 or 2 g/kg body weight of sucrose 2 hours after the administration of Y-4. As in the preceding example, blood samples were collected from the tail end of mice at different time intervals and assayed for blood sugar levels. Table 2 shows the results of administration of the test compound 30 minutes before sucrose loading and Table 3 shows the results of administration of the test compound 2 hours before sucrose loading, respectively. A significant suppressive effect on the elevation of blood sugar level was observed in a dose responsive manner and delayed absorption of sucrose was demonstrated in groups given 100 mg/kg and 200 mg/kg of Y-4 30 minutes before sucrose loading up to 90 minutes after the sucrose loading as shown in Table 2. Similar results were obtained in the group given 200 mg/kg of Y-4 two hours before sucrose loading as shown in Table 3.
    TABLE 2
    Suppresive effect of Y-4 on the elevation of blood sugar level
    after sucrose loading (30 minutes before sucrose loading)
    Dose Blood sugar level (mg/dl)
    (mg/kg) 20 min. 40 min. 60 min. 90 min.
    Control 40.4 ± 2.3 49.8 ± 1.7 52.9 ± 2.1 52.4 ± 3.0 
     0 79.0 ± 9.4 98.6 ± 7.4 93.2 ± 8.2 82.0 ± 5.0 
     50 71.0 ± 5.9  90.8 ± 10.0 76.6 ± 9.9 68.0 ± 8.1 
    100  50.8 ± 2.4*  59.3 ± 2.4* 72.9 ± 2.6 60.6 ± 2.3* 
    200  40.4 ± 0.4**  53.2 ± 7.5**  58.2 ± 8.7* 57.6 ± 3.2**
  • [0016]
    TABLE 3
    Suppressive effect of Y-4 on the elevation of blood sugar
    level after sucrose loading (2 hours before sucrose loading)
    Dose Blood sugar level (mg/dl)
    (mg/kg) 20 min. 40 min. 60 min. 90 min.
    Control 53.2 ± 8.1 66.8 ± 16.7 80.6 ± 19.9 68.8 ± 19.8
     0 102.2 ± 14.5 121.2 ± 16.1  142.8 ± 20.7  118.4 ± 10.5 
    200  66.2 ± 6.3*  84.6 ± 8.9**  94.0 ± 18.0*  94.4 ± 17.2*
  • 3. Effect of Y-4 on blood sugar and insulin levels in mice having experimental diabetes after sucrose loading [0017]
  • Experimental diabetes was induced in mice by treating the mice with streptozocin (STZ) (100 mg/kg/day i.p. for two days). After fasting for 17-24 hours, the mice were orally given Y-4 at varying [0018] doses 30 minutes before loading 2 g/kg of sucrose. After sucrose loading, blood samples were collected and assayed for blood sugar levels at different time intervals as in the preceding examples. The results are shown in Table 4. Administration of Y-4 30 minutes before sucrose loading remarkably suppressed the elevation of blood sugar level up to 3 hours.
    TABLE 4
    Suppressive effect of Y-4 on the elevation of sugar level in
    mice having experimental diabetes after sucrose loading
    Dose Blood sugar level (mg/dl)
    (mg/kg) 20 min. 40 min. 60 min. 90 min. 180 min.
    Control 84.0 ± 3.9
     0 178.8 ± 340.2 ± 329.4 ± 270.8 ± 284.9 ±
    27.7 40.0 46.1 34.2 30.3
    200 96.8 ± 134.2 ± 138.2 ± 137.0 ± 131.8 ±
    10.3* 15.6** 15.6* 24.7* 15.6*
  • Similar to the above experiments, Y-4 was orally administered to the mice having experimental diabetes at a dose of 100 mg/[0019] kg 30 minutes before loading of 2 g of sucrose. Blood sugar and insulin levels in blood samples collected 30 minutes after sugar loading are shown in FIG. 1 and FIG. 2, respectively. Administration of Y-4 30 minutes before sucrose loading suppressed the elevation of blood sugar level almost completely whereas insulin level increased to a value which is not significantly different from the control value of normal mice group.
  • 4. Inhibitory effect of Y-4 on intestinal α-glucosidase activity of normal mouse [0020]
  • Intestinal tract enucleated from a normal mouse was homogenized by the conventional method after removing membrane mucosa. As a substrate, sucrose, starch, maltose or isomaltose was used. The homogenate was incubated with the substrate in the presence of a test compound (Y-4 or zinc chloride) at 37° C. for 30 minutes. The reaction mixture was centrifuged and the glucose concentration in the resulting supernatant was assayed. The glucose assay was conducted calorimetrically by adding a chromogenic reagent (0.47 mol/l of orthotoluidine, 16 mol/l of acetic acid, 10 mmol/l of boric acid) to the supernatant, heating the mixture in a boiling water bath for 8 minutes and measuring the absorbance at 635 nm. α-Glucosidase activity expressed in terms of glucose concentration/mg protein was calculated. The results are shown in Table 5 through Table 8 below. Y-4 inhibited α-glucosidase activity in the reaction with all substrates at a concentration higher than 5 mM in a dose responsive manner. Zinc chloride used for comparative purpose was as effective as Y-4 to inhibit the enzymatic reaction with sucrose but not effective with other substrates. [0021]
    TABLE 5
    Inhibition of glucose production from sucrose (normal mouse)
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
     0 5.239 ± 0.073 5.239 ± 0.073
     5 3.509 ± 0.254 4.078 ± 0.073
    10 1.658 ± 0.078 1.682 ± 0.097
    30 0.714 ± 0.097 0.726 ± 0.157
    50 0.133 ± 0.024 0.436 ± 0.036
  • [0022]
    TABLE 6
    Inhibition of glucose production from starch (normal mouse)
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
     0 4.961 ± 0.000 5.264 ± 0.254 
     5 4.755 ± 0.109 4.211 ± 0.073 
    10 4.441 ± 0.182 3.400 ± 0.036**
    30 3.703 ± 0.532 1.162 ± 0.024**
    50 2.795 ± 0.085 0.339 ± 0.121**
  • [0023]
    TABLE 7
    Inhibition of glucose production from maltose (normal mouse)
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
     0 23.026 ± 1.137 23.232 ± 0.230 
     5 19.917 ± 0.932 17.956 ± 0.423 
    10 18.114 ± 0.145 14.810 ± 0.956* 
    30 15.657 ± 0.036 10.963 ± 0.399**
    50 10.442 ± 0.290  5.353 ± 0.017**
  • [0024]
    TABLE 8
    Inhibition of glucose production from isomaltose (normal mouse)
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
     0 6.982 ± 0.085 6.933 ± 0.859 
     5 6.207 ± 0.230 5.009 ± 0.387 
    10 5.868 ± 0.496 4.150 ± 0.351* 
    30 6.510 ± 0.169 3.473 ± 0.520**
    50 5.421 ± 0.339 3.158 ± 0.206**
  • 5. Inhibitory effect of Y-4 on intestinal α-glucosidase activity of streptozocin-induced diabetic mouse [0025]
  • Example 5 was repeated using intestinal tract enucleated from a diabetic mouse induced by the treatment with streptozocin instead of intestinal tract enucleated from a normal mouse to determine the inhibitory effect of Y-4 on α-glycosidase activity. The results are shown in Table 9 through Table 12 below. The intestinal α-glucosidase activity was higher in streptozocin-induced diabetic mouse than in normal mouse. Y-4 remarkably inhibited the enzyme in the reaction with all substrates. The inhibitory effect of Y-4 was more remarkable in the diabetic mouse than in normal mouse. ZnCl[0026] 2 used for comparative purpose showed only weak inhibitory effects.
    TABLE 9
    Inhibition of glucose production from sucrose (diabetic mouse)
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
     0 16.190 ± 1.174 16.129 ± 0.073
     5 13.346 ± 0.411 10.128 ± 1.137
    10  6.716 ± 0.145  5.312 ± 1.113
    30  5.772 ± 0.121  3.146 ± 0.157
    50  4.973 ± 0.024  2.251 ± 0.327
  • [0027]
    TABLE 10
    Inhibition of glucose production from starch (diabetic mouse)
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
     0 16.021 ± 0.058 16.230 ± 0.093  
     5 12.240 ± 0.733 8.249 ± 0.419* 
    10  9.191 ± 0.081 5.631 ± 0.151**
    30 10.204 ± 0.209 2.118 ± 0.175**
    50  8.866 ± 0.291 0.640 ± 0.070**
  • [0028]
    TABLE 11
    Inhibition of glucose production from maltose (diabetic
    mouse
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
    0 32.903 ± 0.058 32.682 ± 0.023
    5 28.691 ± 1.222 23.060 ± 1.129
    10 20.698 ± 0.442  18.569 ± 1.617*
    30 21.175 ± 0.105  15.113 ± 0.093**
    50 21.838 ± 0.652  12.793 ± 0.337**
  • [0029]
    TABLE 12
    Inhibition of glucose production from isomaltose (diabetic
    mouse
    Inhibitor
    concentration Glucose (mg/mg protein)
    (mM) ZnCl2 Y-4
    0 6.003 ± 0.268 6.364 ± 0.303 
    5 5.945 ± 0.256 3.188 ± 0.035* 
    10 5.038 ± 0.535 2.571 ± 0.233**
    30 5.794 ± 0.803 1.943 ± 0.047**
    50 6.027 ± 0.221 1.303 ± 0.430**
  • 6. Improvement of insulin resistance in mice with type II diabetes [0030]
  • Y-4 was orally administered to male Wistar fatty rats (WFR) having tyep II diabetes with obesity and hyperlipidemia at an average daily dose of 150 mg/kg for consecutive 8 weeks. Eight weeks after the initiation of administration, the rats were fasted for 20 hours and then given oral administration of 2.5 g/kg/rat of glucose. Blood samples were collected from the tail vein at 30, 60, 120 and 180 minutes after the administration of glucose for assaying blood sugar and insulin levels. The results are shown in FIG. 3 and FIG. 4, respsectively. The blood sugar level was significantly controlled in the group treated with Y-4 as shown in FIG. 3 and the insulin level was normalized in the same group as shown in FIG. 4. This demonstrates that long term administration of Y-4 may improve the insulin resistance. [0031]
  • The acute toxicity of zinc tranexamate monohydrate (Y-4) is known to be very low since no death was observed in a toxicity test wherein 1,200 mg/kg of Y-4 was orally administered to mice. Other adverse effects are not known with respect to Y-4. Accordingly, the present invention provides an effective and highly safe treatment of diabetes by drug therapy for a long term. [0032]
  • Zinc tranexamate or monohydrate thereof may be orally administered either in the form of solid preparations such as tablets, granules, powders or capsules or in the form of liquid preparations such as syrups or other liquid preparations. Zinc tranexamate is known to form a water-soluble complex with a physiologically nontoxic organic acid such as acetic, glycolic, lactic, succinic, malic, tartaric maleic or fumaric acid. Liquid preparations may be formulated using this soluble complex. These solid and liquid preparations may be produced using the method well-known in the art by processing the active ingredient with a pharmaceutically acceptable carrier. [0033]
  • The dose may vary depending on the conditions of the disease, age and body weight of a particular patient and generally lies between 300 mg and 2,000 mg as zinc tranexamate per day for adult patients. This daily dose may be divided into 3 to 4 fractions for oral administration. [0034]

Claims (6)

We claim:
1. A method for the treatment of diabetes comprising orally administering a therapeutically effective amount of a zinc tranexamate compound to a patient with diabetes.
2. A method according to
claim 1
 wherein said zinc tranexamate compound is selected from the group consisting of zinc tranexamate, monohydrate thereof, and a complex thereof with a physiologically nontoxic organic acid.
3. A method according to
claim 1
 wherein the diabetes is type II diabetes.
4. A method according to
claim 1
 wherein the diabetes is insulin-resistant type II diabetes.
5. A method according to
claim 1
 wherein the zinc tranexamate compound is administered in admixture with a pharmaceutical carrier for solid preparations.
6. A method according to
claim 1
 wherein the zinc tranexamate compound is administered in admixture with a pharmaceutical carrier for liquid preparations.
US09/799,692 2000-03-08 2001-03-07 Use of zinc tranexamate in the treatment of diabetes Expired - Fee Related US6358999B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000062880A JP2001247458A (en) 2000-03-08 2000-03-08 Therapeutic agent for diabetes comprising zinc tranexmate compound
JP2000-062880 2000-03-08
JP62880/2000 2000-03-08
CA002340556A CA2340556A1 (en) 2000-03-08 2001-03-12 Use of zinc tranexamate in the treatment of diabetes

Publications (2)

Publication Number Publication Date
US20010031785A1 true US20010031785A1 (en) 2001-10-18
US6358999B2 US6358999B2 (en) 2002-03-19

Family

ID=25682443

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/799,692 Expired - Fee Related US6358999B2 (en) 2000-03-08 2001-03-07 Use of zinc tranexamate in the treatment of diabetes

Country Status (4)

Country Link
US (1) US6358999B2 (en)
EP (1) EP1132083B1 (en)
JP (1) JP2001247458A (en)
CA (1) CA2340556A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
WO2007025332A1 (en) * 2005-08-29 2007-03-08 Dia-B Tech Limited A peptide and zinc ion composition for treating diabetes and enhancing immune function
US8541367B2 (en) 2009-03-12 2013-09-24 Landing Biotech, Inc. Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof
US9018159B2 (en) 2009-03-12 2015-04-28 Landing Biotech, Inc. Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5759847A (en) * 1980-09-29 1982-04-10 Hisamitsu Pharmaceut Co Inc 4-aminomethylcyclohexanecarboxylic acid derivative
JPS60163813A (en) * 1984-02-04 1985-08-26 Morishita Jintan Kk Antiplasmin drug
EP0532706B1 (en) * 1990-06-04 1995-05-10 Health Now REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
JPH06502184A (en) * 1991-02-22 1994-03-10 シャピロ，ハワード　ケイ． Use of medicinal compounds for the treatment of symptoms of neurological diseases or causally related symptoms
DE4214215A1 (en) * 1992-04-30 1993-11-04 Behringwerke Ag USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION
JPH0725724B2 (en) * 1992-06-23 1995-03-22 財団法人生産開発科学研究所 Zinc tranexamate
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases

Also Published As

Publication number Publication date
US6358999B2 (en) 2002-03-19
EP1132083A2 (en) 2001-09-12
EP1132083B1 (en) 2004-08-11
CA2340556A1 (en) 2002-09-12
EP1132083A3 (en) 2002-10-23
JP2001247458A (en) 2001-09-11

Similar Documents

Publication Publication Date Title
EP1377278B1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
EP1303304B1 (en) Pharmaceutical combinations for treatment and prevention of diabetes mellitus
EP1741446B1 (en) Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US7893113B2 (en) Materials and methods for modulating metabolism
WO2009015560A1 (en) Use of allylcysteine or its analogs and pharmaceutical composition threrof
JPH10510241A (en) Use of ketoconazole and related substances as a therapeutic agent for type II diabetes
CZ382799A3 (en) Use of zinc hyaluronate against peptic ulcers
JP3088787B2 (en) Sucrase activity inhibitor
US6358999B2 (en) Use of zinc tranexamate in the treatment of diabetes
CN111195247B (en) Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs
US6740667B2 (en) Antimicrobial agent
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
WO2021036884A1 (en) Application of hernandezine or pharmaceutically acceptable salt thereof in drugs for diabetes or diabetic complications
EP0451869B1 (en) Use of steroid derivatives in the treatment of endometriosis
US6642236B1 (en) Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
CN115814007B (en) Alpha-glucosidase inhibitor and preparation method and application thereof
US8557831B2 (en) Compositions and methods for treatment and prevention of insulin resistance
US20210238216A1 (en) Pharmaceutical agents, compositions, and methods relating thereto
US5036081A (en) Calcium absorption promoter
RU2435593C2 (en) Pharmaceutical composition for treatment of type 2 diabetes mellitus and medicine on its basis
EP0485232A1 (en) Neovascularisation inhibitors
JP2616845B2 (en) Blood cholesterol lowering agent containing cysteinolic acid or a bile acid conjugate thereof
DE60104747T2 (en) Use of zinc tranexamate for the treatment of diabetes
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
Keen et al. The uses of biguanides in diabetes mellitus

Legal Events

Date Code Title Description
AS Assignment

Owner name: HAMARI CHEMICALS, LTD., OF, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUJIMURA, HAJIME;NOZAKI, MASAKATSU;TANAKA, SHAN-ICHI;AND OTHERS;REEL/FRAME:011681/0075;SIGNING DATES FROM 20010122 TO 20010129

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20100319

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载